Age-Related Macular Degeneration (AMD)OASISNCT07660640
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
An observational study of Age-Related Macular Degeneration (AMD) and Non-Neovascular Age-Related Macular Degeneration, run by Perceive Biotherapeutics, Inc. at 4 sites in 2 countries.
Trial summary
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
- What is being tested?
- observational study and VOY-101
- Type of treatment
- Injection or infusion
- How many people
- 88 participants
- Where
- 4 sitesin 2 countries
- Study dates
- 3 Mar 2026to 30 Aug 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
Who may be able to join
- Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101.
- Are willing and able to understand and provide informed consent.
Who cannot join
- There are no exclusion criteria for this study
Trial locations and contacts
4 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
4 sites in 2 countries
United States3 sites
Retina Consultants of Texas
Bellaire, Texas, 77401
Ophthalmic Consultants of Boston
Boston, Massachusetts, 02114
University of Utah
Salt Lake City, Utah, 84132
About this study
Official title: Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
Read the detailed description
This is a long-term observational, non-interventional extension study to the Phase 1/2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).
- Being tested
- observational study, VOY-101
- Keywords
- Long term follow up, extension study
- Medical subject headings
- Macular Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
observational studyOther
No intervention - observational study
VOY-101Biological
One-time intravitreal injection of VOY-101.
| Study group | Role | What they receive |
|---|---|---|
| Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101 | Long-term safety extension from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101 Receives: Other: observational study; Biological: VOY-101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of ocular and systemic VOY-101 related AEs
Frequency of ocular and systemic VOY-101 related AEs (serious [SAEs] and treatment-emergent non-serious adverse events [TEAEs]).
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start3 Mar 2026
- Primary completion30 Jul 2031 (estimated)
- Study completion30 Aug 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age-Related Macular Degeneration (AMD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07660640
- Sponsor's protocol ID
- PBI-AMD-901
- Acronym
- OASIS
- Status last verified
- Feb 2026
- First submitted
- 16 Jun 2026
- Last updated
- 22 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long-Term Follow Up of VOY-101 for Advanced Non-Neovascular Age-Related Macular Degeneration Extension Study
- ClinicalTrials.gov ID
- NCT07660640
- Acronym / sponsor ID
- OASIS / PBI-AMD-901
- Keywords
- Long term follow up, extension study
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- Perceive Biotherapeutics, Inc.Industry (pharma, biotech, devices)
- Study start
- 3 Mar 2026 (actual)
- Primary completion
- 30 Jul 2031 (estimated)
- Study completion
- 30 Aug 2031 (estimated)
- First posted
- 22 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
Detailed description
This is a long-term observational, non-interventional extension study to the Phase 1/2a studies that administered VOY-101 to subjects with advanced non-neovascular age-related macular degeneration (AMD).
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101 | – | Other: observational study, Biological: VOY-101Long-term safety extension from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101 |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
Key inclusion criteria (2 listed)
- Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101.
- Are willing and able to understand and provide informed consent.
Key exclusion criteria (1 listed)
- There are no exclusion criteria for this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| observational studyNo intervention - observational study | Other | Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101 |
| VOY-101One-time intravitreal injection of VOY-101. | Biological | Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101 |
Primary outcome
Frequency of ocular and systemic VOY-101 related AEs
Time frame: 3 years
Frequency of ocular and systemic VOY-101 related AEs (serious [SAEs] and treatment-emergent non-serious adverse events [TEAEs]).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Age-Related Macular Degeneration (AMD)
RecruitingPhase 2
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Geographic Atrophy Secondary to Age-Related Macular Degeneration
RecruitingObservational study
National Eye Institute Biorepository for Retinal Diseases
Age-Related Macular Degeneration, Diabetic Retinopathy
Active, not recruitingPhase 3
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Enrolling by invitation
Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study
Geographic Atrophy
Active, not recruitingPhase 1/2
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
Age-Related Macular Degeneration
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Age-Related Macular Degeneration (AMD) and Non-Neovascular Age-Related Macular Degeneration, run by Perceive Biotherapeutics, Inc. at 4 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 22 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States, Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of ocular and systemic VOY-101 related AEs (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2026.